Compare SFL & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SFL | SDGR |
|---|---|---|
| Founded | 2003 | 1990 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.8B |
| IPO Year | 2004 | 2020 |
| Metric | SFL | SDGR |
|---|---|---|
| Price | $10.88 | $31.74 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 7 |
| Target Price | $13.30 | ★ $33.57 |
| AVG Volume (30 Days) | 1.4M | ★ 1.6M |
| Earning Date | 11-04-2026 | 11-04-2026 |
| Dividend Yield | ★ 8.19% | N/A |
| EPS Growth | N/A | ★ 45.14 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $255,869,000.00 |
| Revenue This Year | $14.48 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 23.29 |
| 52 Week Low | $7.52 | $10.95 |
| 52 Week High | $13.98 | $33.78 |
| Indicator | SFL | SDGR |
|---|---|---|
| Relative Strength Index (RSI) | 31.10 | 60.28 |
| Support Level | $10.73 | $11.27 |
| Resistance Level | $11.30 | $32.15 |
| Average True Range (ATR) | 0.45 | 2.50 |
| MACD | -0.19 | 0.59 |
| Stochastic Oscillator | 15.37 | 78.65 |
SFL Corp Ltd is an international ship-owning and chartering company. The company is engaged in transporting crude oil and oil products, dry bulk and containerized cargoes, freight of rolling cargo, and offshore drilling and related activities. The company operates as a single reportable segment, generating revenue from long-term, fixed-rate charters. Its Additional revenue sources include sales-type lease interest income, voyage charter and pool revenues, and drilling contract revenues.
Schrodinger Inc is a healthcare-based software company. It offers software solutions designed to support and accelerate the discovery, design, and optimization of molecules. The company operates in two reportable segments: Software and Drug Discovery. The software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on generating revenue from a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have various stages of discovery and development. The majority of the company's revenue is derived from the Software segment. Geographically, it derives the maximum revenue from the United States.